Prospective study of CIPN in patients undergoing gemcitabine plus nab-PTX for pancreatic cancer

Prospective study of CIPN in patients undergoing gemcitabine plus nab-PTX for pancreatic cancer - Prospective study of CIPN in patients undergoing gemcitabine plus nab-PTX for pancreatic cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045287

Enrollment

Registered

2021-08-27

Start date

2021-08-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) patients who plan to undergo gemcitabine plus nab-PTX between August 2021 and June 2022 2) age>= 20 years 3) providing written informed consent

Exclusion criteria

Exclusion criteria: 1) Judgement by doctors

Design outcomes

Primary

Measure	Time frame
serum pNF-H value	—

Secondary

Measure	Time frame
CTCAE, Numeric rating scale, Grip and release test, FACT/GOG NTX	—

Countries

Japan

Contacts

Public ContactYurie Tokitou

Graduate School of Medicine, The University of Tokyo Department of Gastroenterology

yurie_a_0620@yahoo.co.jp03-3815-5411

Outcome results